Back to top
more

Neurocrine Biosciences (NBIX)

(Delayed Data from NSDQ)

$135.99 USD

135.99
717,575

-1.77 (-1.28%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of 23.38% and 0.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) to Report Q2 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?

by Zacks Equity Research

Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Stevanato (STVN): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Stevanato (STVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Neurocrine Biosciences (NBIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -403.85% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Zoetis (ZTS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDYG

Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -23.48% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should SPDR S&P 400 Mid Cap Growth ETF (MDYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for MDYG

3 Reasons Growth Investors Will Love Neurocrine (NBIX)

by Zacks Equity Research

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows

by Zacks Equity Research

Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.

Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance

by Zacks Equity Research

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.

Is Kura Oncology (KURA) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Kura Oncology (KURA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.

Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Zoetis' (ZTS) earnings miss estimates in second-quarter 2022. The revenues beat estimates owing to the strong uptake of the company's companion animal portfolio products.

Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is set to report impressive earnings and revenues and provide an update on its pipeline when it releases second-quarter 2022 results.

Assertio (ASRT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Assertio Holdings' (ASRT) second-quarter performance is likely to reflect the sales performance of its marketed drugs and cost savings from the company's restructuring plans.

    Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

    by Zacks Equity Research

    Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.